Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomet acquires anticoagulant specialist

This article was originally published in Clinica

Executive Summary

Orthopaedics firm Biomet has bought anticoagulant maker Cytosol Laboratories in order to secure a critical supply for its platelet separation and concentration technology. Cytosol was founded in 1968 and develops three proprietary anticoagulants to aid in the processing of blood components. It markets noClot-50; TriCitrasol, which is used for anticoagulation during granulocytapheresis; and Rejuvesol, which rejuvenates stored, frozen red blood cells prior to transfusion. Biomet (Warsaw, Indiana) said that the anticoagulants would be used in its GPS III platelet separation system and BioCue platelet concentration system, which are used to concentrate and mix a combination of blood and bone marrow. Biomet secured all of the assets of the Braintree, Massachusetts firm for an undisclosed fee.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel